ArticleCancer imaging : the official publication of the International Cancer Imaging Society2023
Evaluating the value of
Article in Cancer imaging : the official publication of the International Cancer Imaging Society, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Diagnostic Performance of 18F-prostate-specific Membrane Antigen-1007 PET/CT in the Detection of Prostate Cancer
The Role of 18F-PSMA PET in Prostate Cancer Diagnosis in Equivocal MRI: a Multi-center Randomised Controlled Trial
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy of [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Pooled it
- Prospective comparison ofEuropean journal of nuclear medicine and molecular imaging · 2025Trial
- Diagnostic impact of interpretation criteria for [European journal of nuclear medicine and molecular imaging · 2026Article
- Diagnostic value of PRIMARY score and a combined model with SUVmax in 18F-PSMA-1007 PET/CT for prostate cancer.Frontiers in medicine · 2026Article
- Radiomics Features from Different Prostatic Zones onCancers · 2025Article
- The Role of 18F PSMA-1007 PET/CT in the Staging and Detection of Recurrence of Prostate Cancer, A Scoping Review.Cancers · 2025Review
- The accuracy of fluorine 18-labelled prostate-specific membrane antigen PET/CT and MRI for diagnosis of prostate cancer in PSA grey zone.British journal of cancer · 2025Observational
- Agreement between PSMA-RADS and E-PSMA systems in classifying [Frontiers in medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundProstate-specific membrane antigen (PSMA) PET/CT is a highly regarded radionuclide imaging modality for prostate cancer (PCa). This study aimed to evaluate the diagnostic performance of
methodsWe retrospectively collected 117 patients who underwent
resultsThe detection rate of
conclusions
trial registrationClinicalTrials.gov Identifier: NCT04521894, Registered: August 17, 2020.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.